- Home
- INMB vs CRVO Comparison
INMB vs CRVO Comparison
Compare INMB & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- CRVO
- Stock Information
- Founded
- INMB 2015
- CRVO 2001
- Country
- INMB United States
- CRVO United States
- Employees
- INMB N/A
- CRVO N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- CRVO Health Care
- Exchange
- INMB Nasdaq
- CRVO Nasdaq
- Market Cap
- INMB 68.9M
- CRVO 67.4M
- IPO Year
- INMB 2019
- CRVO N/A
- Fundamental
- Price
- INMB $2.53
- CRVO $10.12
- Analyst Decision
- INMB Buy
- CRVO Strong Buy
- Analyst Count
- INMB 4
- CRVO 6
- Target Price
- INMB $9.53
- CRVO $17.60
- AVG Volume (30 Days)
- INMB 2.9M
- CRVO 820.1K
- Earning Date
- INMB 08-07-2025
- CRVO 08-08-2025
- Dividend Yield
- INMB N/A
- CRVO N/A
- EPS Growth
- INMB N/A
- CRVO N/A
- EPS
- INMB N/A
- CRVO N/A
- Revenue
- INMB $50,000.00
- CRVO $7,776,968.00
- Revenue This Year
- INMB $212.27
- CRVO N/A
- Revenue Next Year
- INMB $10,184.28
- CRVO N/A
- P/E Ratio
- INMB N/A
- CRVO N/A
- Revenue Growth
- INMB N/A
- CRVO N/A
- 52 Week Low
- INMB $1.89
- CRVO $1.80
- 52 Week High
- INMB $11.64
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- INMB 41.61
- CRVO 65.00
- Support Level
- INMB $2.42
- CRVO $9.11
- Resistance Level
- INMB $2.61
- CRVO $9.96
- Average True Range (ATR)
- INMB 0.22
- CRVO 0.79
- MACD
- INMB 0.09
- CRVO 0.06
- Stochastic Oscillator
- INMB 26.67
- CRVO 90.31
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.